CP100356盐酸盐 | 142716-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: CP100356盐酸盐
• 英文名称: 4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine
• CAS: 142716-85-6
• 化学式: C₃₁H₃₆N₄O₆
• 分子量: 560.6
• InChiKey: PPMZZFZYBXDSRH-UHFFFAOYSA-N

物化性质

• 熔点：
  206-210°C
• 沸点：
  741.9±70.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  96.4
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
  申请人：The Regents of the University of Michigan

  公开号：US10512667B2

  公开（公告）日：2019-12-24

  Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.

  本文提供了治疗与肾上腺皮质活性和/或类固醇分泌过多有关的疾病的方法。特别是，本文提供了通过施用以下至少一种制剂治疗肾上腺皮质活性和/或类固醇分泌过多相关疾病的方法：1）能够抑制与 ABCA1 和/或 ABCG1 相关的胆固醇外流的制剂；2）能够抑制与 MDR1 相关的皮质醇分泌和/或 MDR1 P 糖蛋白多药物转运体活性的制剂；以及 3）能够抑制线粒体活性的制剂。
• Method of increasing the bioavailability and tissue penetration of azithromycin
  申请人：Pfizer Products Inc.

  公开号：EP1127580B1

  公开（公告）日：2006-03-08
• COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ADRENOCORTICAL ACTIVITY AND/OR EXCESSIVE STEROID PRODUCTION
  申请人：The Regents of the University of Michigan

  公开号：US20180369321A1

  公开（公告）日：2018-12-27

  Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.